SEARCH

SEARCH BY CITATION

References

  • 1
    Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E36.
  • 2
    Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996; 38 (Suppl. 2): S1823.
  • 3
    Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004; 11: 97107.
  • 4
    Yeo W, Chan PK, Hui P et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J. Med. Virol. 2003; 70: 55361.
  • 5
    Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975; 2: 52830.
  • 6
    Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975; 68: 10512.
  • 7
    Gwak GY, Koh KC, Kim HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin. Exp. Rheumatol. 2007; 25: 8889.
  • 8
    Ito S, Nakazono K, Murasawa A et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum. 2001; 44: 33942.
  • 9
    Narvaez J, Rodriguez-Moreno J, Martinez-Aguila MD, Clavaguera MT. Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. J. Rheumatol. 1998; 25: 20378.
  • 10
    Ojiro K, Naganuma M, Ebinuma H et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J. Gastroenterol. 2008; 43: 397401.
  • 11
    Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 13635.
  • 12
    Wendling D, Auge B, Bettinger D et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann. Rheum. Dis. 2005; 64: 7889.
  • 13
    Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann. Rheum. Dis. 2003; 62: 6867.
  • 14
    Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 20920.
  • 15
    Yeo W, Zee B, Zhong S et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br. J. Cancer 2004; 90: 130611.
  • 16
    Yeo W, Chan PK, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J. Med. Virol. 2000; 62: 299307.
  • 17
    Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 1828.
  • 18
    Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987–1991. Cancer 1996; 78: 221015.
  • 19
    Kumagai K, Takagi T, Nakamura S et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann. Oncol. 1997; 8 (Suppl. 1): 1079.
  • 20
    Yeo W, Chan PK, Ho WM et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J. Clin. Oncol. 2004; 22: 92734.
  • 21
    Hsu C, Hsiung CA, Su IJ et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008; 47: 84453.
  • 22
    Takai S, Tsurumi H, Ando K et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur. J. Haematol. 2005; 74: 15865.
  • 23
    Marcucci F, Mele A, Spada E et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006; 91: 5547.
  • 24
    Liang RH, Lok AS, Lai CL, Chan TK, Todd D, Chiu EK. Hepatitis B infection in patients with lymphomas. Hematol. Oncol. 1990; 8: 26170.
  • 25
    Lau GK, Leung YH, Fong DY et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002; 99: 232430.
  • 26
    Lau GK, Liang R, Chiu EK, Lee CK, Lam SK. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant. 1997; 19: 7959.
  • 27
    Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J. Clin. Oncol. 1999; 17: 3948.
  • 28
    Lau GK, He ML, Fong DY et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002; 36: 7029.
  • 29
    Knoll A, Boehm S, Hahn J, Holler E, Jilg W. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2004; 33: 9259.
  • 30
    Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int. 2004; 24: 5406.
  • 31
    Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br. J. Cancer 1999; 81: 6974.
  • 32
    Kim MK, Ahn JH, Kim SB et al. Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience. Korean J. Int. Med. 2007; 22: 23743.
  • 33
    Cheng AL. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma. Blood 1996; 87: 1202.
  • 34
    Tur-Kaspa R, Shaul Y, Moore DD et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988; 167: 6303.
  • 35
    Jang JW, Choi JY, Bae SH et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol. 2004; 41: 42735.
  • 36
    Yeo W, Lam KC, Zee B et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann. Oncol. 2004; 15: 16616.
  • 37
    Hui CK, Cheung WW, Zhang HY et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 5968.
  • 38
    Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002; 346: 23542.
  • 39
    Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J. Clin. Oncol. 2004; 22: 47116.
  • 40
    Perceau G, Diris N, Estines O, Derancourt C, Levy S, Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br. J. Dermatol. 2006; 155: 10536.
  • 41
    Wasmuth JC, Fischer HP, Sauerbruch T, Dumoulin FL. Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin's lymphoma. Eur. J. Med. Res. 2008; 13: 4836.
  • 42
    Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46: 10859.
  • 43
    Tsutsumi Y, Kawamura T, Saitoh S et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004; 45: 6279.
  • 44
    Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann. Hematol. 2004; 83: 76974.
  • 45
    Ono K, Iyama S, Matsunaga T et al. [Reactivation of hepatitis B virus due to rituximab plus CHOP after preemptive lamivudine administration in a patient with diffuse large B-cell lymphoma]. Gan To Kagaku Ryoho 2007; 34: 150912.
  • 46
    Sera T, Hiasa Y, Michitaka K et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Int. Med. 2006; 45: 7214.
  • 47
    Tsutsumi Y, Kanamori H, Mori A et al. Reactivation of hepatitis B virus with rituximab. Expert Opin. Drug Saf. 2005; 4: 599608.
  • 48
    Zhong S, Yeo W, Schroder C et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J. Viral. Hepat. 2004; 11: 559.
  • 49
    Tanaka Y, Esumi M, Shikata T. Persistence of hepatitis B virus DNA after serological clearance of hepatitis B virus. Liver 1990; 10: 610.
  • 50
    Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely ‘occult’? Hepatology 2001; 34: 194203.
  • 51
    Hu KQ. Occult hepatitis B virus infection and its clinical implications. J. Viral. Hepat. 2002; 9: 24357.
  • 52
    Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 1996; 2: 11048.
  • 53
    Cabrerizo M, Bartolome J, Caramelo C, Barril G, Carreno V. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. Hepatology 2000; 32: 11623.
  • 54
    Fong TL, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 1993; 18: 131318.
  • 55
    Loriot MA, Marcellin P, Walker F et al. Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. J. Hepatol. 1997; 27: 2518.
  • 56
    Targhetta C, Cabras MG, Mamusa AM, Mascia G, Angelucci E. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica 2008; 93: 9512.
  • 57
    Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N. Engl. J. Med. 2001; 344: 689.
  • 58
    Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J. Infect. Chemother. 2005; 11: 18991.
  • 59
    Westhoff TH, Jochimsen F, Schmittel A et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930.
  • 60
    Onozawa M, Hashino S, Izumiyama K et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005; 79: 61619.
  • 61
    Knoll A, Boehm S, Hahn J, Holler E, Jilg W. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J. Viral. Hepat. 2007; 14: 47883.
  • 62
    Seth P, Alrajhi AA, Kagevi I et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant. 2002; 30: 18994.
  • 63
    Goyama S, Kanda Y, Nannya Y et al. Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation. Leuk Lymphoma 2002; 43: 215963.
  • 64
    Berger A, Preiser W, Kachel HG, Sturmer M, Doerr HW. HBV reactivation after kidney transplantation. J. Clin. Virol. 2005; 32: 1625.
  • 65
    Duhart BT Jr, Honaker MR, Shokouh-Amiri MH et al. Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation. Transpl. Infect. Dis. 2003; 5: 12631.
  • 66
    Cil T, Altintas A, Pasa S, Bayan K, Ozekinci T, Isikdogan A. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy. Leuk Lymphoma 2008; 49: 93947.
  • 67
    Lau GK, Lie A, Liang R. Prophylactic lamivudine therapy for hepatitis B patients undergoing immunosuppressive therapy. Blood 2002; 100: 3054.
  • 68
    Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br. J. Haematol. 2001; 115: 5862.
  • 69
    Ahmed A, Keeffe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am. J. Gastroenterol. 1999; 94: 24951.
    Direct Link:
  • 70
    Yeo W, Steinberg JL, Tam JS et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J. Med. Virol. 1999; 59: 2639.
  • 71
    Simpson ND, Simpson PW, Ahmed AM et al. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine. J. Clin. Gastroenterol. 2003; 37: 6871.
  • 72
    Lim LL, Wai CT, Lee YM et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment. Pharmacol. Ther. 2002; 16: 193944.
  • 73
    Vassiliadis T, Garipidou V, Tziomalos K, Perifanis V, Giouleme O, Vakalopoulou S. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy—a prospective case series. Am. J. Hematol. 2005; 80: 197203.
  • 74
    Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int. 2008; 28: 2838.
  • 75
    Loomba R, Rowley A, Wesley R et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann. Intern. Med. 2008; 148: 51928.
  • 76
    Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 171422.
  • 77
    Kim JS, Hahn JS, Park SY et al. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma. Yonsei Med. J. 2007; 48: 7889.
  • 78
    Law JK, Ali JA, Harrigan PR, Sherlock CH, Savage KJ, Yoshida EM. Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. Am. J. Hematol. 2006; 81: 96972.
  • 79
    Perez-Roldan F, Gonzalez-Carro P, Villafanez-Garcia MC. Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N. Engl. J. Med. 2005; 352: 31011.
  • 80
    Fouillard L, Serfaty L, Gozlan J. Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant. 2006; 37: 6256.
  • 81
    Fung SK, Chae HB, Fontana RJ et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J. Hepatol. 2006; 44: 28390.
  • 82
    Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin. Liver Dis. 2007; 11: 96591, x.
  • 83
    Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment. Pharmacol. Therap. 2006; 24: 100316.
  • 84
    Lau GK, Yiu HH, Fong DY et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 17429.
  • 85
    Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J. Viral. Hepat. 2008; 15: 89102.
  • 86
    Barclay S, Pol S, Mutimer D et al. Erratum to “The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting”[J. Clin. Virol. 41 (4) 2008 243–254]. J. Clin. Virol. 2008; 42: 10415.
  • 87
    Liu CJ, Kao JH, Chen DS. Kinetics of hepatitis B virus reactivation after chemotherapy: more questions than answers. Gastroenterology 2006; 131: 1656; author reply -7.
  • 88
    Hui CK, Cheung WW, Au WY et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54: 1597603.
  • 89
    Lin PC, Poh SB, Lee MY, Hsiao LT, Chen PM, Chiou TJ. Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients. Int. J. Hematol. 2005; 81: 34951.
  • 90
    Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002; 51: 5979.
  • 91
    Saab S, Dong MH, Joseph TA, Tong MJ. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology 2007; 46: 104956.
  • 92
    Yeo W, Ho WM, Hui P et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res. Treat. 2004; 88: 20915.
  • 93
    Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br. J. Haematol. 2002; 116: 1669.
  • 94
    Stroffolini T, Andriani A, Bibas M, Barlattani A. Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma. Ann. Hematol. 2002; 81: 489.
  • 95
    Al-Taie OH, Mork H, Gassel AM, Wilhelm M, Weissbrich B, Scheurlen M. Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature. Ann. Hematol. 1999; 78: 2479.